Fat-soluble seed and shell compounds in this vitamin-C-rich dried fruit quiet inflammation. Strongest signal: modest relief of wear-related joint pain and less need for pain medication. Weaker signals: lower cholesterol, upper blood pressure, deep abdominal fat, and better skin hydration. Safety is unusually benign; loose stools at higher intakes set the practical limit. Almost every positive trial was manufacturer-funded. (Full Review)
| Marker | Target | Why |
|---|---|---|
| High-sensitivity C-reactive protein | Below 1.0 mg/L, ideally below 0.5 mg/L | Tracks the inflammatory signal rose hip may lower |
| LDL cholesterol | Below 100 mg/dL, below 70 mg/dL with established plaque | One of two outcomes with direct human trial support |
| Systolic blood pressure | 110–120 mmHg | The second trial-supported outcome; fastest to move |
| Fasting glucose | 75–86 mg/dL (4.2–4.8 mmol/L) | Baseline for the speculative metabolic signal |
| HbA1c | Below 5.3% | Slower, harder confirmation of any glycemic change |
| Waist circumference | Below 94 cm in men, below 80 cm in women | Proxy for the visceral fat the extract trial targeted |
| Serum ferritin with transferrin saturation | Ferritin 30–100 ng/mL in men, 30–80 ng/mL in women; saturation 20–40% | Rose hip's vitamin C increases plant-source iron absorption |
| 24-hour urinary oxalate | Below 40 mg per 24 hours | Relevant only to prior calcium oxalate stone formers |
| Serum digoxin, only if prescribed | No rose-hip-specific target exists; tracked against the individual's own trough level and clinical state | Falsely elevated on one common assay |
Cadence: Baseline panel before starting; a check at four weeks for tolerability and blood pressure; the full panel repeated at three months, then every six to twelve months. An extra digoxin level or clotting check two weeks in for anyone on digoxin or a vitamin K antagonist.